Clinical Trial Update: Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating TL-925 for allergic conjunctivitis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• TL-925

Snippet

Sponsor: Telios Pharma, Inc. | Conditions: Allergic Conjunctivitis | Phase 2 | Status: RECRUITING